Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial

@article{Janka2007EconomicEO,
  title={Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial},
  author={Hans Uwe Janka and Barbara H{\"o}gy},
  journal={The European Journal of Health Economics},
  year={2007},
  volume={9},
  pages={165-170}
}
In the LAPTOP trial, combination therapy with once-daily insulin glargine + oral antidiabetic agents glimepiride and metformin (BOT) was compared to twice-daily premixed insulin (CT). BOT was safer and more effective than CT. Cost analysis of both regimens were compared over a 1-year period. Analyses were performed from the perspective of the German statutory health insurance. Costs per patient per year were on average €236 lower for BOT than for CT therapy. Economic advantage for BOT was… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-2 of 2 references

Economic evaluation of the LAPTOP-study results

B. Hoegy, H. U. Janka, E. Huppertz
Value Health 8(6), A 164 • 2005
View 1 Excerpt